Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration
Identifieur interne : 001D76 ( Istex/Corpus ); précédent : 001D75; suivant : 001D77Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration
Auteurs : Emma C. Schofield ; Diana Caine ; Jillian J. Kril ; Nicholas J. Cordato ; Glenda M. HallidaySource :
- Movement Disorders [ 0885-3185 ] ; 2005-01.
English descriptors
Abstract
The movement disorders progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) both deposit tau in degenerating neurons and are considered to be tauopathies. The recently developed scheme for staging tissue degeneration in another tauopathy, frontotemporal dementia [Broe et al., Neurology 2003;60:1005–1011] was applied to pathologically confirmed PSP (n = 24) and CBD (n = 9) cases and correlated with clinical indices. In contrast to frontotemporal dementia, the majority of PSP cases had limited or no visible atrophy, while the pattern of atrophy in CBD cases conformed to the existing staging scheme (all but one case exhibiting substantial visible tissue atrophy). Despite similar clinical severity and disease duration between groups, there was a marked difference between the PSP and CBD cases in pathological disease stage (χ2 = 8.86; P = 0.03). The degree of global atrophy in PSP appears to be distinct from other tauopathies, while CBD fits the same pattern as other pathological forms of frontotemporal dementia. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20286
Links to Exploration step
ISTEX:9F073D1FCDB3A7E66F3982825948EC8631FD9849Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration</title><author><name sortKey="Schofield, Emma C" sort="Schofield, Emma C" uniqKey="Schofield E" first="Emma C." last="Schofield">Emma C. Schofield</name><affiliation><mods:affiliation>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick, Australia</mods:affiliation></affiliation></author><author><name sortKey="Caine, Diana" sort="Caine, Diana" uniqKey="Caine D" first="Diana" last="Caine">Diana Caine</name><affiliation><mods:affiliation>Department of Psychology, The University of Sydney, Camperdown, Australia</mods:affiliation></affiliation></author><author><name sortKey="Kril, Jillian J" sort="Kril, Jillian J" uniqKey="Kril J" first="Jillian J." last="Kril">Jillian J. Kril</name><affiliation><mods:affiliation>Centre for Education and Research on Ageing, The University of Sydney, Concord Hospital, Concord, Australia</mods:affiliation></affiliation></author><author><name sortKey="Cordato, Nicholas J" sort="Cordato, Nicholas J" uniqKey="Cordato N" first="Nicholas J." last="Cordato">Nicholas J. Cordato</name><affiliation><mods:affiliation>Department of Geriatric Medicine, Westmead Hospital and The University of Sydney, Westmead, Australia</mods:affiliation></affiliation></author><author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name><affiliation><mods:affiliation>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick, Australia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9F073D1FCDB3A7E66F3982825948EC8631FD9849</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20286</idno><idno type="url">https://api.istex.fr/document/9F073D1FCDB3A7E66F3982825948EC8631FD9849/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001D76</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration</title><author><name sortKey="Schofield, Emma C" sort="Schofield, Emma C" uniqKey="Schofield E" first="Emma C." last="Schofield">Emma C. Schofield</name><affiliation><mods:affiliation>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick, Australia</mods:affiliation></affiliation></author><author><name sortKey="Caine, Diana" sort="Caine, Diana" uniqKey="Caine D" first="Diana" last="Caine">Diana Caine</name><affiliation><mods:affiliation>Department of Psychology, The University of Sydney, Camperdown, Australia</mods:affiliation></affiliation></author><author><name sortKey="Kril, Jillian J" sort="Kril, Jillian J" uniqKey="Kril J" first="Jillian J." last="Kril">Jillian J. Kril</name><affiliation><mods:affiliation>Centre for Education and Research on Ageing, The University of Sydney, Concord Hospital, Concord, Australia</mods:affiliation></affiliation></author><author><name sortKey="Cordato, Nicholas J" sort="Cordato, Nicholas J" uniqKey="Cordato N" first="Nicholas J." last="Cordato">Nicholas J. Cordato</name><affiliation><mods:affiliation>Department of Geriatric Medicine, Westmead Hospital and The University of Sydney, Westmead, Australia</mods:affiliation></affiliation></author><author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name><affiliation><mods:affiliation>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick, Australia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-01">2005-01</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="34">34</biblScope><biblScope unit="page" to="39">39</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9F073D1FCDB3A7E66F3982825948EC8631FD9849</idno><idno type="DOI">10.1002/mds.20286</idno><idno type="ArticleID">MDS20286</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>atrophy</term><term>corticobasal degeneration</term><term>progressive supranuclear palsy</term><term>staging</term><term>tauopathy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="fr">The movement disorders progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) both deposit tau in degenerating neurons and are considered to be tauopathies. The recently developed scheme for staging tissue degeneration in another tauopathy, frontotemporal dementia [Broe et al., Neurology 2003;60:1005–1011] was applied to pathologically confirmed PSP (n = 24) and CBD (n = 9) cases and correlated with clinical indices. In contrast to frontotemporal dementia, the majority of PSP cases had limited or no visible atrophy, while the pattern of atrophy in CBD cases conformed to the existing staging scheme (all but one case exhibiting substantial visible tissue atrophy). Despite similar clinical severity and disease duration between groups, there was a marked difference between the PSP and CBD cases in pathological disease stage (χ2 = 8.86; P = 0.03). The degree of global atrophy in PSP appears to be distinct from other tauopathies, while CBD fits the same pattern as other pathological forms of frontotemporal dementia. © 2004 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Emma C. Schofield BSc (Hons)</name><affiliations><json:string>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick, Australia</json:string></affiliations></json:item><json:item><name>Diana Caine PhD</name><affiliations><json:string>Department of Psychology, The University of Sydney, Camperdown, Australia</json:string></affiliations></json:item><json:item><name>Jillian J. Kril PhD</name><affiliations><json:string>Centre for Education and Research on Ageing, The University of Sydney, Concord Hospital, Concord, Australia</json:string></affiliations></json:item><json:item><name>Nicholas J. Cordato PhD, FRACP</name><affiliations><json:string>Department of Geriatric Medicine, Westmead Hospital and The University of Sydney, Westmead, Australia</json:string></affiliations></json:item><json:item><name>Glenda M. Halliday PhD</name><affiliations><json:string>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick, Australia</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>tauopathy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>corticobasal degeneration</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>progressive supranuclear palsy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>atrophy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>staging</value></json:item></subject><language><json:string>eng</json:string></language><abstract>The movement disorders progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) both deposit tau in degenerating neurons and are considered to be tauopathies. The recently developed scheme for staging tissue degeneration in another tauopathy, frontotemporal dementia [Broe et al., Neurology 2003;60:1005–1011] was applied to pathologically confirmed PSP (n = 24) and CBD (n = 9) cases and correlated with clinical indices. In contrast to frontotemporal dementia, the majority of PSP cases had limited or no visible atrophy, while the pattern of atrophy in CBD cases conformed to the existing staging scheme (all but one case exhibiting substantial visible tissue atrophy). Despite similar clinical severity and disease duration between groups, there was a marked difference between the PSP and CBD cases in pathological disease stage (χ2 = 8.86; P = 0.03). The degree of global atrophy in PSP appears to be distinct from other tauopathies, while CBD fits the same pattern as other pathological forms of frontotemporal dementia. © 2004 Movement Disorder Society</abstract><qualityIndicators><score>5.514</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1076</abstractCharCount><pdfWordCount>3570</pdfWordCount><pdfCharCount>23296</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>162</abstractWordCount></qualityIndicators><title>Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration</title><genre><json:string>Serial article</json:string></genre><host><volume>20</volume><pages><total>6</total><last>39</last><first>34</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/mds.20286</json:string></doi><id>9F073D1FCDB3A7E66F3982825948EC8631FD9849</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/9F073D1FCDB3A7E66F3982825948EC8631FD9849/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/9F073D1FCDB3A7E66F3982825948EC8631FD9849/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/9F073D1FCDB3A7E66F3982825948EC8631FD9849/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2005</date></publicationStmt><notesStmt><note>National Health and Medical Research Council of Australia - No. 113804; No. 157212;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration</title><author><persName><forename type="first">Emma C.</forename><surname>Schofield</surname><roleName type="degree">BSc (Hons)</roleName></persName><affiliation>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick, Australia</affiliation></author><author><persName><forename type="first">Diana</forename><surname>Caine</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Psychology, The University of Sydney, Camperdown, Australia</affiliation></author><author><persName><forename type="first">Jillian J.</forename><surname>Kril</surname><roleName type="degree">PhD</roleName></persName><affiliation>Centre for Education and Research on Ageing, The University of Sydney, Concord Hospital, Concord, Australia</affiliation></author><author><persName><forename type="first">Nicholas J.</forename><surname>Cordato</surname><roleName type="degree">PhD, FRACP</roleName></persName><affiliation>Department of Geriatric Medicine, Westmead Hospital and The University of Sydney, Westmead, Australia</affiliation></author><author><persName><forename type="first">Glenda M.</forename><surname>Halliday</surname><roleName type="degree">PhD</roleName></persName><note type="correspondence"><p>Correspondence: Prince of Wales Medical Research Institute, Barker Street, Randwick, NSW 2031, Sydney, Australia</p></note><affiliation>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick, Australia</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-01"></date><biblScope unit="vol">20</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="34">34</biblScope><biblScope unit="page" to="39">39</biblScope></imprint></monogr><idno type="istex">9F073D1FCDB3A7E66F3982825948EC8631FD9849</idno><idno type="DOI">10.1002/mds.20286</idno><idno type="ArticleID">MDS20286</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="fr"><p>The movement disorders progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) both deposit tau in degenerating neurons and are considered to be tauopathies. The recently developed scheme for staging tissue degeneration in another tauopathy, frontotemporal dementia [Broe et al., Neurology 2003;60:1005–1011] was applied to pathologically confirmed PSP (n = 24) and CBD (n = 9) cases and correlated with clinical indices. In contrast to frontotemporal dementia, the majority of PSP cases had limited or no visible atrophy, while the pattern of atrophy in CBD cases conformed to the existing staging scheme (all but one case exhibiting substantial visible tissue atrophy). Despite similar clinical severity and disease duration between groups, there was a marked difference between the PSP and CBD cases in pathological disease stage (χ2 = 8.86; P = 0.03). The degree of global atrophy in PSP appears to be distinct from other tauopathies, while CBD fits the same pattern as other pathological forms of frontotemporal dementia. © 2004 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>tauopathy</term></item><item><term>corticobasal degeneration</term></item><item><term>progressive supranuclear palsy</term></item><item><term>atrophy</term></item><item><term>staging</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-01-18">Received</change><change when="2004-05-07">Registration</change><change when="2005-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/9F073D1FCDB3A7E66F3982825948EC8631FD9849/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v20:1</doi><numberingGroup><numbering type="journalVolume" number="20">20</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2005-01">January 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="40" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20286</doi><idGroup><id type="unit" value="MDS20286"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2004 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2004-01-18"></event><event type="manuscriptRevised" date="2004-04-28"></event><event type="manuscriptAccepted" date="2004-05-07"></event><event type="publishedOnlineEarlyUnpaginated" date="2004-08-13"></event><event type="firstOnline" date="2004-08-13"></event><event type="publishedOnlineFinalForm" date="2005-01-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">34</numbering><numbering type="pageLast">39</numbering></numberingGroup><correspondenceTo>Prince of Wales Medical Research Institute, Barker Street, Randwick, NSW 2031, Sydney, Australia</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20286.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="38"></count><count type="wordTotal" number="3998"></count></countGroup><titleGroup><title type="main" xml:lang="en">Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration</title><title type="short" xml:lang="en">Severity of Atrophy Distinguishes CBD and PSP</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Emma C.</givenNames><familyName>Schofield</familyName><degrees>BSc (Hons)</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Diana</givenNames><familyName>Caine</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Jillian J.</givenNames><familyName>Kril</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Nicholas J.</givenNames><familyName>Cordato</familyName><degrees>PhD, FRACP</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Glenda M.</givenNames><familyName>Halliday</familyName><degrees>PhD</degrees></personName><contactDetails><email>g.halliday@unsw.edu.au</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="AU" type="organization"><unparsedAffiliation>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick, Australia</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="AU" type="organization"><unparsedAffiliation>Department of Psychology, The University of Sydney, Camperdown, Australia</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="AU" type="organization"><unparsedAffiliation>Centre for Education and Research on Ageing, The University of Sydney, Concord Hospital, Concord, Australia</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="AU" type="organization"><unparsedAffiliation>Department of Geriatric Medicine, Westmead Hospital and The University of Sydney, Westmead, Australia</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">tauopathy</keyword><keyword xml:id="kwd2">corticobasal degeneration</keyword><keyword xml:id="kwd3">progressive supranuclear palsy</keyword><keyword xml:id="kwd4">atrophy</keyword><keyword xml:id="kwd5">staging</keyword></keywordGroup><fundingInfo><fundingAgency>National Health and Medical Research Council of Australia</fundingAgency><fundingNumber>113804</fundingNumber><fundingNumber>157212</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="fr"><title type="main">Abstract</title><p>The movement disorders progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) both deposit tau in degenerating neurons and are considered to be tauopathies. The recently developed scheme for staging tissue degeneration in another tauopathy, frontotemporal dementia [Broe et al., Neurology 2003;60:1005–1011] was applied to pathologically confirmed PSP (n = 24) and CBD (n = 9) cases and correlated with clinical indices. In contrast to frontotemporal dementia, the majority of PSP cases had limited or no visible atrophy, while the pattern of atrophy in CBD cases conformed to the existing staging scheme (all but one case exhibiting substantial visible tissue atrophy). Despite similar clinical severity and disease duration between groups, there was a marked difference between the PSP and CBD cases in pathological disease stage (χ<sup>2</sup> = 8.86; <i>P</i> = 0.03). The degree of global atrophy in PSP appears to be distinct from other tauopathies, while CBD fits the same pattern as other pathological forms of frontotemporal dementia. © 2004 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Severity of Atrophy Distinguishes CBD and PSP</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration</title></titleInfo><name type="personal"><namePart type="given">Emma C.</namePart><namePart type="family">Schofield</namePart><namePart type="termsOfAddress">BSc (Hons)</namePart><affiliation>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Diana</namePart><namePart type="family">Caine</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychology, The University of Sydney, Camperdown, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jillian J.</namePart><namePart type="family">Kril</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Centre for Education and Research on Ageing, The University of Sydney, Concord Hospital, Concord, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nicholas J.</namePart><namePart type="family">Cordato</namePart><namePart type="termsOfAddress">PhD, FRACP</namePart><affiliation>Department of Geriatric Medicine, Westmead Hospital and The University of Sydney, Westmead, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Glenda M.</namePart><namePart type="family">Halliday</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick, Australia</affiliation><description>Correspondence: Prince of Wales Medical Research Institute, Barker Street, Randwick, NSW 2031, Sydney, Australia</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-01</dateIssued><dateCaptured encoding="w3cdtf">2004-01-18</dateCaptured><dateValid encoding="w3cdtf">2004-05-07</dateValid><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">2</extent><extent unit="references">38</extent><extent unit="words">3998</extent></physicalDescription><abstract lang="fr">The movement disorders progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) both deposit tau in degenerating neurons and are considered to be tauopathies. The recently developed scheme for staging tissue degeneration in another tauopathy, frontotemporal dementia [Broe et al., Neurology 2003;60:1005–1011] was applied to pathologically confirmed PSP (n = 24) and CBD (n = 9) cases and correlated with clinical indices. In contrast to frontotemporal dementia, the majority of PSP cases had limited or no visible atrophy, while the pattern of atrophy in CBD cases conformed to the existing staging scheme (all but one case exhibiting substantial visible tissue atrophy). Despite similar clinical severity and disease duration between groups, there was a marked difference between the PSP and CBD cases in pathological disease stage (χ2 = 8.86; P = 0.03). The degree of global atrophy in PSP appears to be distinct from other tauopathies, while CBD fits the same pattern as other pathological forms of frontotemporal dementia. © 2004 Movement Disorder Society</abstract><note type="funding">National Health and Medical Research Council of Australia - No. 113804; No. 157212; </note><subject lang="en"><genre>Keywords</genre><topic>tauopathy</topic><topic>corticobasal degeneration</topic><topic>progressive supranuclear palsy</topic><topic>atrophy</topic><topic>staging</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>34</start><end>39</end><total>6</total></extent></part></relatedItem><identifier type="istex">9F073D1FCDB3A7E66F3982825948EC8631FD9849</identifier><identifier type="DOI">10.1002/mds.20286</identifier><identifier type="ArticleID">MDS20286</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D76 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001D76 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:9F073D1FCDB3A7E66F3982825948EC8631FD9849
|texte= Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration
}}
| This area was generated with Dilib version V0.6.23. |  |